ERBB2 and neoplasm: Immunohistochemical analysis showed heterogeneous expression of erbB2, with distinct erbB2-positive tumor cell populations before chemotherapy in the primary tumor, but negative cells in the liver and bone marrow, with cells staining strongly positive for erbB2 in bone marrow after the three initial cycles of chemotherapy.